Nagasaki University and NEC OncoImmunity collaboration has also led to the establishment of the Vaccine Informatics Department at the Institute of Tropical Medicine, Nagasaki University.
Nagasaki University and NEC OncoImmunity (NOI), a leading artificial intelligence (AI) company, have announced that they will collaborate to use NOI’s AI platform to design universal vaccines against highly pathogenic and tropical infectious diseases.
The collaboration between NOI and Nagasaki University aims to harness the power of advanced AI to optimize vaccine designs to be universally and broadly protective against certain pathogen families prevalent in tropical regions. Under the scope of the collaboration, the AI technology from NOI will be used to design both T cell and B cell vaccines. Nagasaki University will subsequently validate the designs using their extensive “wet-lab” capabilities and convalescent donor samples collected from their extensive network of tropical field stations.
This collaboration has also led to the establishment of the Vaccine Informatics Department at the Institute of Tropical Medicine, Nagasaki University. The department, led by Dr. Trevor Clancy, Chief Scientific Officer of NOI, will employ its AI technology to support the Nagasaki University team in conducting basic research aimed at understanding the immune correlates of protection across a range of tropical diseases. Members of NEC’s AI drug development team will also participate in this department.
Professor Takeshi Nagayasu, M.D., Ph.D., Trustee (Strategic Development and Research), Nagasaki University
“We are delighted to embark on this collaboration with NEC OncoImmunity in our pursuit of designing universal vaccines targeting tropical infectious diseases. By combining the expertise of Nagasaki University in tropical medicine with the advanced AI technology of NEC, we aim to make significant strides in vaccine development for the benefit of global health.”
Richard Stratford, CEO of NOI, expressed his enthusiasm about the collaboration, stating:
“NOI’s core AI technology is well suited for the development of universal vaccines, and we are fully committed to delivering effective vaccine designs to Nagasaki University that target highly pathogenic and tropical infectious diseases. We are immensely proud of this collaboration with such a world-renowned tropical medicine institute, and we anticipate significant outcomes from this project.”
Masamitsu Kitase, Corporate Senior VP, Head of the Healthcare and Life Science Division, NEC Corporation, commented:
“The NEC Group is very excited by this collaboration with Nagasaki University, which will demonstrate interdisciplinary research between computer technology and knowledge for Tropical Medicine, and promises to make significant contributions to vaccine development. Infectious diseases have gained even more attention following the recent pandemic, and NEC is committed to using its state-of-art AI technology to develop effective vaccines in this space.”
Also read: CISO’s role in cyber insurance
CIO News, a proprietary of Mercadeo, produces award-winning content and resources for IT leaders across any industry through print articles and recorded video interviews on topics in the technology sector such as Digital Transformation, Artificial Intelligence (AI), Machine Learning (ML), Cloud, Robotics, Cyber-security, Data, Analytics, SOC, SASE, among other technology topics